Clinical Epileptology, published by Springer Heidelberg, is an emerging open-access journal that aims to advance the understanding of epilepsy through rigorous research and clinical studies. With an ISSN of 2948-104X and E-ISSN of 2948-1058, this journal serves as a vital platform for researchers, clinicians, and students within the fields of Neurology, Pediatrics, and Perinatology. Although still in its formative years, spanning from 2023 to 2024, the journal aspires to fill the knowledge gaps in epilepsy research, thereby improving patient outcomes. Despite its initial Scopus rankings placing it within the 12th and 19th percentiles in respective categories, Clinical Epileptology is poised to make a significant impact by fostering interdisciplinary collaboration and disseminating high-quality findings. With options for open access, this journal ensures that groundbreaking research is readily available to a global audience, encouraging the ongoing dialogue that is crucial to advancing the field. Intended for a diverse readership, including academic researchers, healthcare professionals, and students, Clinical Epileptology is committed to becoming a cornerstone of epilepsy research.

Welcome to the Journal of Central Nervous System Disease, a premier Open Access publication dedicated to advancing the understanding of neurological disorders and their underlying mechanisms. Published by SAGE Publications Ltd, this esteemed journal has been serving the scientific community since 2009 and is committed to disseminating high-quality research that spans from clinical neurology to cellular and molecular neuroscience. With an impressive impact factor, the journal ranks within the top quartiles—Q2 in both Neurology and Clinical Neurology, and Q3 in Cellular and Molecular Neuroscience as of 2023. The journal's indexing in Scopus reflects its significant contribution to the field, being ranked #83 out of 400 in clinical neurology and #38 out of 97 in cellular and molecular neuroscience. This essential resource, based in the United States, is crucial for researchers, clinicians, and students looking to stay at the forefront of neurological science. By providing Open Access options, we ensure that groundbreaking research is readily available to a global audience, fostering collaboration and innovation in the study of central nervous system diseases.

Current Journal of Neurology, published by Tehran University of Medical Sciences, is an esteemed Open Access journal dedicated to advancing the field of neurology. Since its inception in 2011, the journal has provided a platform for innovative research and critical discourse in neurology and clinical neurology, with a focus on the latest advancements and methodologies. Although the journal currently holds a Q4 quartile ranking in both neurology and clinical neurology, its goal is to foster the global dissemination of knowledge and ideas relevant to the complexities of neurological disorders. Researchers, professionals, and students exploring this dynamic field will find valuable insights, as the journal aims to bridge the gap between emerging research and clinical application. Based in Tehran, Iran, the Current Journal of Neurology welcomes contributions that enhance understanding and treatment of neurological conditions, thereby promoting evidence-based practices across the globe.

CNS DRUGS is a leading journal dedicated to the field of neuroscience, specifically focused on the advancement of pharmacological therapies for central nervous system disorders. Published by ADIS INT LTD, this esteemed journal has maintained a strong impact within its domain, achieving Q1 rankings in 2023 across multiple categories, including Neurology (clinical), Pharmacology (medical), and Psychiatry and Mental Health. With an impressive Scopus ranking as the 11th of 272 in medical pharmacology and high percentiles in psychiatry and neurology, it fosters high-quality research publication and dissemination. Spanning over two decades from 1994 to 2024, CNS DRUGS serves as a vital resource for researchers, professionals, and students alike, providing comprehensive insights that drive innovation in clinical practices. Although primarily a subscription-based journal, the richness of its content makes it an essential addition to any institution's library. Striving to bridge the gap between scientific research and clinical application, CNS DRUGS is positioned at the forefront of neurological and psychiatric pharmacotherapy research.

BRAIN & DEVELOPMENT is a prestigious academic journal published by ELSEVIER, renowned for its pivotal contributions to the fields of developmental neuroscience, neurology, and pediatrics. Established in 1979, this journal has become an essential resource for researchers and clinicians alike, as it explores the complexities of brain development and associated neurological disorders in children. With an impactful focus on advancing scientific understanding, BRAIN & DEVELOPMENT is currently ranked in the Q3 quartile in Developmental Neuroscience and Clinical Neurology and Q2 in Pediatrics, reflecting its significance within the medical community. Its ISSN 0387-7604 and E-ISSN 1872-7131 underline its established presence in academic literature. While the journal does not offer open access options, it continues to be a key platform for disseminating new research findings and fostering innovation in the understanding of pediatric neurological health. The journal's commitment to quality research is further evidenced by its ongoing publication trajectory up until 2024, making it a vital source of knowledge for students, professionals, and educators in related fields.

Epilepsy & Behavior Reports, a distinguished journal published by ELSEVIER SCIENCE INC, specializes in the latest research and developments in the field of epilepsy and related behavioral conditions. Since its inception in 2019 as a fully Open Access journal, it has carved a niche for itself within the scientific community, providing an essential platform for researchers and clinicians focused on behavioral neuroscience and neurology. The journal's commitment to disseminating high-quality research is reflected in its current rankings within Scopus, placing it within the Q3 category for Behavioral Neuroscience and Clinical Neurology, underscoring its relevance to emerging trends in these fields. Located in the heart of New York, the journal strives to foster collaboration and innovation, making it a vital resource for academics, practitioners, and students eager to advance their understanding of epilepsy and its behavioral implications. The convergence of expertise and research in Epilepsy & Behavior Reports promises to illuminate crucial aspects of neurological health, driving forward the discourse that shapes future treatment and understanding of epilepsy.

Progress in Neurology and Psychiatry is a pivotal journal published by John Wiley & Sons Ltd, dedicated to advancing the fields of neurology and psychiatry. With a robust history dating back to its establishment, this esteemed journal holds a consistent Q3 ranking in 2023 across several categories including Neurology, Clinical Neurology, Psychiatry, and Mental Health, signifying its significant contribution to the scientific community. This journal serves as a vital source of knowledge and insight, publishing original research, reviews, and case studies that explore the intricacies of neurological and psychiatric disorders. Although it does not offer open access, the journal remains accessible to a wide audience through institutional subscriptions. By fostering a platform for scholarly discourse, Progress in Neurology and Psychiatry aims to bridge the gap between research and practice, ultimately enhancing the quality of care for individuals with neurological and psychiatric conditions. Researchers, clinicians, and students are encouraged to engage with the journal's comprehensive content to stay informed of the latest developments and emerging trends in these critical fields of medicine.

Neurology and Therapy, published by SPRINGER LONDON LTD, stands as a pivotal platform for researchers and practitioners in the field of neurology and its therapeutic applications. This Open Access journal, active since 2012, facilitates the dissemination of innovative studies and cutting-edge findings aimed at improving neurological health. With an impressive ranking in the 2023 Scopus Rankings, where it holds a Q2 category in Neurology and a Q1 category in Clinical Neurology, it underscores its prominence in advancing neurological research. The journal's intriguing scope encompasses a wide-ranging exploration of neurological disorders, treatment methodologies, and healthcare strategies, making it a valuable resource for those vested in enhancing patient outcomes. With an appealing average impact factor, readers are encouraged to dive into the latest advancements and engage with the scholarly discussions that are shaping the future of neurology.

Annals of Indian Academy of Neurology is a premier open access journal dedicated to advancing the field of Neurology, serving as a vital resource for researchers, healthcare professionals, and students since its inception in 2006. Published by the esteemed Wolters Kluwer Medknow Publications, this journal has established itself within the academic community, boasting a Q3 quartile ranking in clinical neurology according to the 2023 category quartiles and a Scopus rank placing it in the 35th percentile among 400 comparable journals. With a focus on clinical advancements and research innovations in neurology, the journal aims to disseminate high-quality and impactful studies that address the complex challenges faced in the neurological landscape, particularly within the Indian context. The open access model ensures that the latest research is readily accessible to a global audience, thereby promoting collaboration and knowledge sharing within the neurosciences.

Seminars in Pediatric Neurology, published by W B SAUNDERS CO-ELSEVIER INC, is a prestigious journal dedicated to the evolving field of pediatric neurological disorders. Since its inception in 1994, this peer-reviewed journal has provided critical insights and cutting-edge research to support healthcare professionals in enhancing the quality of care for children with neurological conditions. With an impressive 2023 impact factor and a Q2 ranking in both the clinical neurology and pediatrics categories, it stands as a vital resource, fostering the dissemination of knowledge among researchers and clinicians alike. Featuring articles that explore a range of topics from clinical trials to innovative treatment modalities, this journal empowers practitioners with the latest findings in pediatric neurology. While primarily subscription-based, it plays a key role in bridging the gap between academia and clinical practice, making it an indispensable tool for anyone involved in the care and treatment of pediatric neurological patients.